|
Q2 FY2026
As of Jul 31, 2025
|
Q1 FY2026
As of Apr 30, 2025
|
Q4 FY2025
As of Jan 31, 2025
|
Q3 FY2025
As of Oct 31, 2024
|
Q2 FY2025
As of Jul 31, 2024
|
Q1 FY2025
As of Apr 30, 2024
|
Q4 FY2024
As of Jan 31, 2024
|
Q3 FY2024
As of Oct 31, 2023
|
Q2 FY2024
As of Jul 31, 2023
|
Q1 FY2024
As of Apr 30, 2023
|
Q4 FY2023
As of Jan 31, 2023
|
Q3 FY2023
As of Oct 31, 2022
|
Q2 FY2023
As of Jul 31, 2022
|
Q1 FY2023
As of Apr 30, 2022
|
Q4 FY2022
As of Jan 31, 2022
|
Q3 FY2022
As of Oct 31, 2021
|
Q2 FY2022
As of Jul 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets: | |||||||||||||||||
| Current assets | |||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||
| Short-term investments | |||||||||||||||||
| Accounts receivable, net | |||||||||||||||||
| Deferred commissions | |||||||||||||||||
| Prepaid expenses and other current assets | |||||||||||||||||
| Total current assets | |||||||||||||||||
| Property and equipment, net | |||||||||||||||||
| Operating lease right-of-use assets | |||||||||||||||||
| Deferred commissions, noncurrent | |||||||||||||||||
| Other assets | |||||||||||||||||
| Total assets | |||||||||||||||||
| Liabilities and Stockholders’ Equity: | |||||||||||||||||
| Current liabilities | |||||||||||||||||
| Accounts payable | |||||||||||||||||
| Accrued compensation and benefits | |||||||||||||||||
| Other accrued liabilities | |||||||||||||||||
| Other accrued expenses | |||||||||||||||||
| Operating lease liabilities | |||||||||||||||||
| Deferred revenue | |||||||||||||||||
| Total current liabilities | |||||||||||||||||
| Operating lease liabilities, noncurrent | |||||||||||||||||
| Deferred revenue, noncurrent | |||||||||||||||||
| Other liabilities | |||||||||||||||||
| Total liabilities | |||||||||||||||||
| Stockholders’ equity | |||||||||||||||||
| Preferred stock, $0.00001 par value; 200,000,000 shares authorized as of July 31, 2025 and January 31, 2025; zero shares issued outstanding as of July 31, 2025 and January 31, 2025 | |||||||||||||||||
| Common stock, $0.00001 par value; 1,000,000,000 shares authorized as of July 31, 2025 and January 31, 2025; 55,248,577 and 53,078,742 shares issued and outstanding as of July 31, 2025 and January 31, 2025, respectively | |||||||||||||||||
| Additional paid-in capital | |||||||||||||||||
| Accumulated other comprehensive income | |||||||||||||||||
| Accumulated deficit | |||||||||||||||||
| Total stockholders’ equity | |||||||||||||||||
| Total liabilities and stockholders’ equity | |||||||||||||||||
Loading...
